Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Phase 3 Recruiting
360 enrolled
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
386 enrolled
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
233 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Phase 1/2 Recruiting
182 enrolled
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
Phase 2 Recruiting
148 enrolled
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Phase 1 Recruiting
110 enrolled
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Recruiting
1,100 enrolled
Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
Phase 1 Recruiting
40 enrolled
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Phase 2 Recruiting
377 enrolled
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Phase 2 Recruiting
87 enrolled
PIKALO-1
Phase 1/2 Recruiting
720 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
THRIVE
Recruiting
1,000 enrolled
Charlie-2
Phase 2 Recruiting
200 enrolled
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Phase 1/2 Recruiting
54 enrolled
GLORIOSA
Phase 3 Recruiting
520 enrolled
PARIB-OLD-PRO²
Recruiting
50 enrolled
EVEREST-2
Phase 1/2 Recruiting
474 enrolled
Spatially Fractionated Radiation Treatment for Gynaecological Cancers
Phase NA Recruiting
20 enrolled
ACTengine
Phase 1/2 Recruiting
375 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Phase 1 Recruiting
171 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Phase 1 Recruiting
100 enrolled
BASECAMP-1
Recruiting
200 enrolled
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Phase 1/2 Recruiting
460 enrolled
Endometrial Cell Collection With the PadKit
Phase NA Recruiting
80 enrolled
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Phase 3 Recruiting
710 enrolled
NCG-Compliance
Recruiting
618 enrolled
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
796 enrolled
EXoPERT EMERALD Clinical Study
Recruiting
1,400 enrolled
SURGE
Phase NA Recruiting
300 enrolled
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Phase 1/2 Recruiting
152 enrolled
ELEPHAS-05
Recruiting
2,000 enrolled
EPICOL-R
Recruiting
120 enrolled
CCANED-CIPHER
Recruiting
6,000 enrolled
ELEPHAS-02
Recruiting
416 enrolled
ON-5001
Phase 1 Recruiting
168 enrolled
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
158 enrolled
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Phase 1 Recruiting
130 enrolled
Study of GV20-0251 in Participants With Solid Tumor Malignancies
Phase 1/2 Recruiting
350 enrolled
DETERMINE
Phase 2/3 Recruiting
30 enrolled
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Phase 1 Recruiting
149 enrolled
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Phase 2 Recruiting
270 enrolled
MAN-U
Phase NA Recruiting
278 enrolled
A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 Recruiting
345 enrolled
Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer
Phase NA Recruiting
20 enrolled
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 Recruiting
70 enrolled
DP-PAN-CANCER
Phase NA Recruiting
450 enrolled